¼¼°èÀÇ ½Ì±Û¼¿ ¿À¹Í½º ½ÃÀå
Single-Cell Omics
»óǰÄÚµå : 1777557
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 389 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ½Ì±Û¼¿ ¿À¹Í½º ½ÃÀåÀº 2030³â±îÁö 43¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Ì±Û¼¿ ¿À¹Í½º ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 15.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 43¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½Ì±Û¼¿ À¯ÀüüÇÐÀº CAGR 17.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 21¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ì±Û¼¿ Àü»çüÇÐ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR13.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 9,880¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR20.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Ì±Û¼¿ ¿À¹Í½º ½ÃÀåÀº 2024³â¿¡´Â 4¾ï 9,880¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 20.9%·Î 2030³â±îÁö ¿¹Ãø ½ÃÀå ±Ô¸ð 9¾ï 5,880¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 11.2%¿Í 14.0%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 12.3%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ½Ì±Û¼¿ ¿À¹Í½º ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

½Ì±Û¼¿ ¿À¹Í½º°¡ »ýÀÇÇÐ ¿¬±¸¸¦ ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡? Á¤¹ÐÀÇ·á¿Í Áúº´ ÀÌÇØ¿¡ À־ÀÇ ¿ªÇÒ¿¡ ´ëÇØ ¾Ë¾Æº¾´Ï´Ù.

´ÜÀÏ ¼¼Æ÷ÇÐ ºÐ¾ß´Â °úÇÐÀÚµéÀÌ ´ë·®ÀÇ ¼¼Æ÷ Áý´ÜÀ¸·ÎºÎÅÍÀÇ ½ÅÈ£¸¦ Æò±ÕÈ­ÇÏ´Â ´ë½Å °³º° ¼¼Æ÷ÀÇ ºÐÀÚ ¹× À¯ÀüÀû Ư¼ºÀ» ºÐ¼®ÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á »ýÀÇÇÐ ¿¬±¸¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ¼¼Æ÷ÀÇ ÀÌÁú¼º¿¡ ´ëÇÑ Àü·Ê ¾ø´Â ÅëÂû·ÂÀ» Á¦°øÇÏ¿© ¿¬±¸ÀÚµéÀÌ Èñ±ÍÇÑ ¼¼Æ÷ Áý´ÜÀ» ¿¬±¸Çϰí, Áúº´ÀÇ ÁøÇàÀ» ÃßÀûÇϰí, »õ·Î¿î Ä¡·á Ç¥ÀûÀ» ¹ß°ßÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ½Ì±Û¼¿ ¿À¹Í½ºÀº ´ÜÀϼ¼Æ÷À¯ÀüüÇÐ, Àü»çüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐ µî ¿©·¯ ºÐ¾ß¸¦ ¾Æ¿ì¸£¸ç, ÀÌ ¸ðµç ºÐ¾ß´Â ¼¼Æ÷ ±â´É¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÎ ÀÌÇØ¿¡ ±â¿©ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¼¼Æ÷ÀÇ ´Ù¾ç¼ºÀÌ Áúº´ ¸ÞÄ¿´ÏÁò¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â Á¾¾çÇÐ, ¸é¿ªÇÐ, ½Å°æ°úÇÐ, Àç»ýÀÇÇÐ ºÐ¾ß¿¡¼­ ƯÈ÷ À¯¿ëÇÏ°Ô È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ÀÇ °íÇØ»óµµ ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á, ½Ì±Û¼¿¿À¹Í½º´Â ¿¬±¸ÀÚµéÀÌ º¸´Ù Á¤¹ÐÇÑ Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖµµ·Ï µ½°í, Á¤¹ÐÀÇ·á·Î °¡´Â ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÇコÄɾ ´ëÇÑ °úÇÐÀû °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÷´Ü ´ÜÀÏ ¼¼Æ÷ ºÐ¼® µµ±¸¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

½Ì±Û¼¿¿À¹Í½º¸¦ °­È­ÇÏ´Â ±â¼ú ¹ßÀüÀ̶õ? µ¥ÀÌÅÍ ºÐ¼® ¹× ±â±â Çõ½ÅÀÇ µ¥ÀÌÅÍ ºÐ¼® ¹× °ËÁõ

ÃÖ±Ù ½ÃÄö½Ì ±â¼ú, ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ¹ßÀüÀº ´ÜÀÏ ¼¼Æ÷ÇÐ ¿¬±¸ÀÇ È¿À²¼º°ú È®À强À» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì(NGS) Ç÷§ÆûÀº ¾×ÀûÃþ ¹× ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º¸¦ ÀÌ¿ëÇÑ ¼¼Æ÷ ºÐ¸® ±â¼ú°ú °áÇÕÇÏ¿©, ÇÏÀ̽º·çDz ´ÜÀÏ ¼¼Æ÷ ºÐ¼®ÀÌ °¡´ÉÇϸç, ¼öõ °³ÀÇ ¼¼Æ÷¸¦ µ¿½Ã¿¡ ó¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)µµ µ¥ÀÌÅÍ ºÐ¼®À» °­È­ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¿¬±¸ÀÚµéÀº ¹æ´ëÇÏ°í º¹ÀâÇÑ µ¥ÀÌÅÍ ¼¼Æ®¿¡¼­ ÀÇ¹Ì ÀÖ´Â »ý¹°ÇÐÀû ÅëÂû·ÂÀ» µµÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐ µ¥ÀÌÅ͸¦ ÇÔ²² ºÐ¼®ÇÏ´Â ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ÅëÇÕÀ¸·Î ¼¼Æ÷ÀÇ °Åµ¿À» º¸´Ù ÃÑüÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ Á¶»ç ±â¼úÀÇ ÀçÇö¼º, ¹Î°¨µµ, ºñ¿ë È¿À²¼ºÀÌ °³¼±µÇ¾î Çмú ¿¬±¸, ÀÓ»ó ¿¬±¸ µî ¸ðµç ºÐ¾ß¿¡¼­ º¸´Ù ½±°Ô Ȱ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ´ÜÀÏ ¼¼Æ÷ ºÐ¼® ÅøÀº ´õ¿í Á¤±³ÇØÁ® ½Å¾à °³¹ß ¹× Áúº´ ¸ðµ¨¸µ¿¡ ´ëÇÑ Àû¿ëÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Ì±Û¼¿¿À¹Í½º µµÀÔÀÇ °É¸²µ¹Àº ¹«¾ùÀΰ¡? ºñ¿ë, º¹À⼺, µ¥ÀÌÅÍ ºÐ¼®ÀÇ ¹®Á¦ ÇØ°á

½Ì±Û¼¿ ¿À¹Í½º´Â ±× Çõ½ÅÀû °¡´É¼º¿¡µµ ºÒ±¸ÇÏ°í ³ôÀº ºñ¿ë, ±â¼úÀû º¹À⼺, µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÇÑ°è µî ¿©·¯ °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ´ÜÀϼ¼Æ÷ ºÐ¼® ¹× ¸ÖƼ¿À¹Í½º ÇÁ·ÎÆÄÀϸµ¿¡ ÇÊ¿äÇÑ Àåºñ¿Í ½Ã¾àÀº ¿©ÀüÈ÷ °í°¡À̸ç, ÀÚ¿ø¿¡ Á¦¾àÀÌ ÀÖ´Â ¿¬±¸ ȯ°æ¿¡¼­ÀÇ È°¿ëÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀ̾³ª ¾ÆÆ¼ÆÑÆ®¸¦ µµÀÔÇÏÁö ¾Ê°í ´ÜÀÏ ¼¼Æ÷¸¦ ºÐ¸®-ó¸®ÇÏ´Â µ¥ ÇÊ¿äÇÑ ±â¼úÀû Àü¹® Áö½ÄÀº ¸¹Àº ¿¬±¸¼Ò¿¡¼­ ¾î·Á¿òÀ» °Þ°í ÀÖ´Â ½ÇÁ¤ÀÔ´Ï´Ù. ´ÜÀÏ ¼¼Æ÷ÇÐ ¿¬±¸¿¡¼­ »ý¼ºµÇ´Â ¹æ´ëÇÑ ¾çÀÇ µ¥ÀÌÅÍ´Â °è»ê»óÀÇ ¹®Á¦¸¦ ¾ß±âÇϸç, À̸¦ È¿À²ÀûÀ¸·Î ÀúÀåÇÏ°í ºÐ¼®Çϱâ À§Çؼ­´Â °íµµÀÇ »ý¹°Á¤º¸ÇÐ Åø°ú Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀÌ ÇÊ¿äÇÕ´Ï´Ù. ½ÇÇè ÇÁ·ÎÅäÄݰú µ¥ÀÌÅÍ ºÐ¼®ÀÇ Ç¥ÁØÈ­´Â ¿©ÀüÈ÷ Áß¿äÇÑ °úÁ¦Àε¥, ±â¼úÀÇ ÆíÂ÷°¡ ¿¬±¸¸¶´Ù Àϰü¼º ¾ø´Â °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ºñ¿ë È¿À²ÀûÀÎ ±â¼ú¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ, °è»ê ÅøÀÇ °³¼±, ±×¸®°í ¿¬±¸ÀÇ ½Å·Ú¼º°ú ÀçÇö¼ºÀ» º¸ÀåÇϱâ À§ÇÑ Ç¥ÁØÈ­µÈ ¿öÅ©Ç÷ο찡 ÇÊ¿äÇÕ´Ï´Ù.

½Ì±Û¼¿ ¿À¹Í½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡? ÁÖ¿ä È®´ë ¿äÀÎ ¹× »ê¾÷ µ¿Çâ ÆÄ¾Ç

´ÜÀϼ¼Æ÷ü ½ÃÀåÀÇ ¼ºÀåÀº Á¤¹ÐÀÇ·á ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡, ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü, ¾Ï ¹× ½Å°æÅðÇ༺ Áúȯ°ú °°Àº º¹ÀâÇÑ ÁúȯÀÇ À¯º´·ü Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× ¹Î°£ ±â°üÀº »ý¹°ÀÇÇÐ ¹ß°ß ¹× ÀǾàǰ °³¹ßÀ» °¡¼ÓÈ­Çϱâ À§ÇØ ´ÜÀÏ ¼¼Æ÷ ºÐ¼® Åø¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ ´ëÇÑ ´ÏÁî°¡ Áõ°¡Çϸ鼭 ÀÓ»ó ¿¬±¸ ¹× Áø´Ü¿¡ ½Ì±Û¼¿ ¿À¹Í½ºÀÇ µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ´ÜÀÏ ¼¿ µ¥ÀÌÅÍ ºÐ¼®¿¡ AI¿Í Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀ» ÅëÇÕÇÔÀ¸·Î½á ¿öÅ©Ç÷ο찡 ´õ¿í °£¼ÒÈ­µÇ°í, ÀÌ·¯ÇÑ ±â¼úÀº ´õ ³ÐÀº ¹üÀ§¿¡¼­ Ȱ¿ëµÉ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»çµéÀº Ç¥ÀûÄ¡·áÁ¦ °³¹ß ¹× ¸ÂÃãÄ¡·á Àü·«¿¡ ½Ì±Û¼¿¿À¹Í½º¸¦ Ȱ¿ëÇÏ¿© ½ÃÀåÀÇ »ó¾÷Àû °¡´É¼ºÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ´ÜÀÏ ¼¼Æ÷ÇÐ ½ÃÀåÀº Å©°Ô ¼ºÀåÇÏ¿© Áúº´À» Á¶»çÇÏ°í ¼¼Æ÷ ¼öÁØ¿¡¼­ Ä¡·áÇÏ´Â ¹æ¹ý¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(½Ì±Û¼¿ À¯ÀüüÇÐ, ½Ì±Û¼¿ Àü»çüÇÐ, ½Ì±Û¼¿ ´Ü¹éÁúüÇÐ, ½Ì±Û¼¿ ´ë»çüÇÐ), ¿ëµµ(Á¾¾çÇÐ, ¼¼Æ÷»ý¹°ÇÐ, ½Å°æÇÐ, ¸é¿ªÇÐ), ÃÖÁ¾ ¿ëµµ(Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú±â°ü ¹× ¿¬±¸±â°ü,º´¿ø ¹× Áø´Ü½ÇÇè½Ç, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Single-Cell Omics Market to Reach US$4.3 Billion by 2030

The global market for Single-Cell Omics estimated at US$1.8 Billion in the year 2024, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 15.4% over the analysis period 2024-2030. Single-Cell Genomics, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Single-Cell Transcriptomics segment is estimated at 13.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$498.8 Million While China is Forecast to Grow at 20.9% CAGR

The Single-Cell Omics market in the U.S. is estimated at US$498.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$958.8 Million by the year 2030 trailing a CAGR of 20.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 14.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.

Global Single-Cell Omics Market - Key Trends & Drivers Summarized

How Is Single-Cell Omics Transforming Biomedical Research? Exploring Its Role in Precision Medicine and Disease Understanding

The field of single-cell omics has revolutionized biomedical research by enabling scientists to analyze the molecular and genetic characteristics of individual cells, rather than averaging signals from bulk cell populations. This approach provides unprecedented insights into cellular heterogeneity, allowing researchers to study rare cell populations, track disease progression, and uncover new therapeutic targets. Single-cell omics encompasses multiple disciplines, including single-cell genomics, transcriptomics, proteomics, and metabolomics, all of which contribute to a more comprehensive understanding of cellular functions. These techniques have proven particularly valuable in oncology, immunology, neuroscience, and regenerative medicine, where cellular diversity plays a critical role in disease mechanisms. By enabling high-resolution profiling of cells, single-cell omics is helping researchers develop more targeted therapies, paving the way for precision medicine. As scientific interest in personalized healthcare grows, the demand for advanced single-cell analysis tools continues to expand, fueling market growth.

What Technological Advancements Are Enhancing Single-Cell Omics? Examining Innovations in Data Analysis and Instrumentation

Recent advancements in sequencing technologies, microfluidics, and bioinformatics have significantly improved the efficiency and scalability of single-cell omics studies. Next-generation sequencing (NGS) platforms, combined with droplet-based and microfluidic cell isolation techniques, have enabled high-throughput single-cell analysis, making it possible to process thousands of cells simultaneously. Artificial intelligence (AI) and machine learning (ML) have also played a critical role in enhancing data interpretation, allowing researchers to extract meaningful biological insights from vast and complex datasets. Additionally, the integration of multi-omics approaches, where genomics, proteomics, and metabolomics data are analyzed together, has provided a more holistic view of cellular behavior. These innovations have improved the reproducibility, sensitivity, and cost-effectiveness of single-cell omics technologies, making them more accessible for both academic and clinical research settings. As technology continues to evolve, single-cell analysis tools are expected to become even more sophisticated, expanding their applications in drug discovery and disease modeling.

What Challenges Are Hindering the Adoption of Single-Cell Omics? Addressing Cost, Complexity, and Data Interpretation Issues

Despite its transformative potential, the widespread adoption of single-cell omics faces several challenges, including high costs, technical complexity, and data analysis limitations. The instrumentation and reagents required for single-cell sequencing and multi-omics profiling remain expensive, limiting their accessibility in resource-constrained research environments. Additionally, the technical expertise needed to isolate and process single cells without introducing bias or artifacts poses a challenge for many laboratories. The massive volume of data generated by single-cell omics studies also presents computational challenges, requiring advanced bioinformatics tools and cloud-based platforms for efficient storage and analysis. Standardization across experimental protocols and data interpretation remains a key issue, as variability in techniques can lead to inconsistent results across different studies. Addressing these challenges requires continued investment in cost-effective technologies, improved computational tools, and standardized workflows to ensure the reliability and reproducibility of single-cell omics research.

What’s Driving the Growth of the Single-Cell Omics Market? Identifying Key Expansion Factors and Industry Trends

The growth in the single-cell omics market is driven by several factors, including increasing funding for precision medicine research, advancements in sequencing technology, and the rising prevalence of complex diseases such as cancer and neurodegenerative disorders. Governments and private organizations are heavily investing in single-cell analysis tools to accelerate biomedical discoveries and drug development. Additionally, the growing need for early disease detection and biomarker discovery has boosted the adoption of single-cell omics in clinical research and diagnostics. The integration of AI and cloud computing in single-cell data analysis has further streamlined workflows, making these technologies more accessible for a broader range of applications. Moreover, pharmaceutical companies are leveraging single-cell omics for targeted drug development and personalized treatment strategies, expanding the commercial potential of the market. With continued technological advancements and increasing demand for precision healthcare, the single-cell omics market is poised for substantial growth, revolutionizing how diseases are studied and treated at the cellular level.

SCOPE OF STUDY:

The report analyzes the Single-Cell Omics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, Single-Cell Metabolomics); Application (Oncology, Cell Biology, Neurology, Immunology); End-Use (Pharma & Biotech Companies, Academic & Research Organizations, Hospital & Diagnostic Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â